GlaxoSmithKline plc and Stiefel Laboratories Inc announced that they have signed an agreement to create a new world-leading specialist dermatology business.
Under the terms of the agreement GSK will acquire the total share capital of Stiefel for a cash consideration of $2.9 billion. GSK also expects to assume $0.4 billion of net debt upon closing. A potential further $0.3 billion cash payment is contingent on future performance.
The details can be read here.
No comments:
Post a Comment